MPM BioVentures 2014, L.P. - Oct 1, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
10%+ Owner
Signature
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.
Stock symbol
ITOS
Transactions as of
Oct 1, 2021
Transactions value $
-$745,525
Form type
4
Date filed
10/5/2021, 04:32 PM
Previous filing
Sep 30, 2021
Next filing
Oct 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Sale -$185K -6.86K -0.21% $27.00 3.28M Oct 1, 2021 See Footnote F1, F2, F3, F4
transaction ITOS Common Stock Sale -$560K -20.7K -0.63% $27.06 3.26M Oct 4, 2021 See Footnote F1, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
F2 The shares were sold as follows: 4,084 by MPM BioVentures 2014, L.P. ("BV 2014"), 141 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,579 by MPM BioVentures 2018, L.P. ("BV 2018") and 51 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The shares are held as follows: 1,858,629 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 63,972 by AM BV2014, 1,173,870 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 23,167 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
F5 The shares were sold as follows: 12,339 by BV 2014, 425 by AM BV2014, 7,793 by BV 2018 and 154 by AM BV2018.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The shares are held as follows: 1,846,290 by BV 2014, 107,713 by BV 2014(B), 63,547 by AM BV2014, 1,166,077 by BV 2018, 54,213 by BV 2018(B) and 23,013 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Remarks:

See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.